课题基金 / 基金详情

ACTG 254--MICRONIZED ATOVAQUONE & AZITHROMYCIN VS TRIMETHOPRIM/SULFAMETHAXZOLE

ACTG 254--MICRONIZED ATOVAQUONE & AZITHROMYCIN VS TRIMETHOPRIM/SULFAMETHAXZOLE
ACTG 254--微粉化阿托伐醌
批准号：
6276334
负责人：
HENRY S SACKS
金额：
$6.67万
依托单位：
MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6276334
关键词：
atovaquone azithromycin bacterial disease chemoprevention clinical research combination chemotherapy drug adverse effect drug screening /evaluation human subject human therapy evaluation pharmacokinetics sulfamethoxazole trimethoprim

项目摘要

项目成果

HENRY S SACKS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The study seeks to determine the comparability of azithromycin plus atovaquone to TMP/SMX in prevention of serious bacterial infections. It will also determine and compare the long-term safety and tolerance (as defined by the rate of treatment-limiting adverse events) of micronized atovaquone plus azithromycin versus TMP/SMX. For the first 30 patients, the study will examine if there is a likelihood of pharmacokinetic interaction between atovaquone and azithromycin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Meta-analysis of CAM therapies for HIV
Meta-analysis of CAM therapies for HIV
Meta-analysis of CAM therapies for HIV
Meta-analysis of CAM therapies for HIV
海外基金